IZD334 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 106 | Cryopyrin-associated periodic syndrome | 1 |
106. Cryopyrin-associated periodic syndrome
Clinical trials : 42 / Drugs : 24 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04086602 (ClinicalTrials.gov) | September 13, 2019 | 9/9/2019 | Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334 | A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants as Well as an Open-label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic Syndromes | Healthy Volunteers;Cryopyrin Associated Periodic Syndrome | Drug: IZD334;Drug: Placebos | Inflazome UK Ltd | NULL | Completed | 18 Years | 65 Years | All | 64 | Phase 1 | Australia |